Pub Date : 2025-12-01Epub Date: 2025-02-04DOI: 10.1080/21645515.2025.2460272
Laiping Xie, Yuhang Wang, Andi Wan, Lin Huang, Qing Wang, Wanyan Tang, Xiaowei Qi, Xiaofei Hu
The approach of neoadjuvant therapy for breast cancer, which involves administering systemic treatment prior to primary surgery, has undergone substantial advancements in recent decades. This strategy is intended to reduce tumor size, thereby enabling less invasive surgical procedures and enhancing patient outcomes. This study presents a comprehensive bibliometric analysis of research trends in neoadjuvant therapy for breast cancer from 2009 to 2024. Using data extracted from the Web of Science Core Collection, a total of 3,674 articles were analyzed to map the research landscape in this field. The analysis reveals a steady increase in publication output, peaking in 2022, with the United States and China identified as the leading contributors. Key institutions, such as the University of Texas System and MD Anderson Cancer Center, have been instrumental in advancing the research on neoadjuvant therapy. The study also highlights the contributions of influential authors like Sibylle Loibl and Gunter von Minckwitz, as well as major journals such as the Journal of Clinical Oncology. Emerging research topics, including immunotherapy, liquid biopsy, and artificial intelligence, are gaining prominence and represent potential future directions for clinical applications. This bibliometric analysis provides critical insights into global research trends, key contributors, and future developments in the field of neoadjuvant therapy for breast cancer, offering a foundation for future research and clinical practice advancements.
{"title":"Research trends of neoadjuvant therapy for breast cancer: A bibliometric analysis.","authors":"Laiping Xie, Yuhang Wang, Andi Wan, Lin Huang, Qing Wang, Wanyan Tang, Xiaowei Qi, Xiaofei Hu","doi":"10.1080/21645515.2025.2460272","DOIUrl":"10.1080/21645515.2025.2460272","url":null,"abstract":"<p><p>The approach of neoadjuvant therapy for breast cancer, which involves administering systemic treatment prior to primary surgery, has undergone substantial advancements in recent decades. This strategy is intended to reduce tumor size, thereby enabling less invasive surgical procedures and enhancing patient outcomes. This study presents a comprehensive bibliometric analysis of research trends in neoadjuvant therapy for breast cancer from 2009 to 2024. Using data extracted from the Web of Science Core Collection, a total of 3,674 articles were analyzed to map the research landscape in this field. The analysis reveals a steady increase in publication output, peaking in 2022, with the United States and China identified as the leading contributors. Key institutions, such as the University of Texas System and MD Anderson Cancer Center, have been instrumental in advancing the research on neoadjuvant therapy. The study also highlights the contributions of influential authors like Sibylle Loibl and Gunter von Minckwitz, as well as major journals such as the Journal of Clinical Oncology. Emerging research topics, including immunotherapy, liquid biopsy, and artificial intelligence, are gaining prominence and represent potential future directions for clinical applications. This bibliometric analysis provides critical insights into global research trends, key contributors, and future developments in the field of neoadjuvant therapy for breast cancer, offering a foundation for future research and clinical practice advancements.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2460272"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11801352/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Increasing the uptake of Human Papillomavirus (HPV) vaccine among adolescent girls is a high priority for the government of Bangladesh. This study examines correlates of HPV vaccine adoption in Dhaka Division, the largest division in Bangladesh. The 18-day vaccination campaign was accompanied by multimedia messages. We use the Fogg Behavior Model (FBM) as the theoretical framework for our analysis. Using a survey instrument based on the FBM, we analyze cross-sectional data collected from 611 caregivers of girls aged 9-17 in Dhaka. Survey data was collected in November and December 2023. Caregivers were recruited via Facebook and Instagram ads and interviewed through the Facebook Messenger App. About one-third of caregivers reported that their child had been vaccinated. We conducted bivariate and multivariate analyses to assess the relationships between the caregivers' motivation, ability, exposure to the campaign and their child's vaccination status. Adjusted odds ratios from logistic regression analyses, suggest that caregivers' motivation, ability, and exposure to the multimedia campaign contributed to vaccine uptake. Caregivers' motivation to get their child vaccinated was high (74%) but their ability was low (20%). Exposure to campaign messages had a dose-response relationship with vaccine adoption. However, 48% of caregivers remained unexposed to the multimedia campaign. We discuss challenges that the government's HPV vaccination program is likely to face and identify program-related research questions that are important to answer for the success of future vaccination efforts.
{"title":"Effects of a multimedia campaign to increase human papillomavirus vaccine acceptance in Dhaka, Bangladesh.","authors":"Sohail Agha, Sarah Francis, Drew Bernard, Aslam Fareed, Kasrina Azad, Firdausi Qadri","doi":"10.1080/21645515.2024.2447105","DOIUrl":"10.1080/21645515.2024.2447105","url":null,"abstract":"<p><p>Increasing the uptake of Human Papillomavirus (HPV) vaccine among adolescent girls is a high priority for the government of Bangladesh. This study examines correlates of HPV vaccine adoption in Dhaka Division, the largest division in Bangladesh. The 18-day vaccination campaign was accompanied by multimedia messages. We use the Fogg Behavior Model (FBM) as the theoretical framework for our analysis. Using a survey instrument based on the FBM, we analyze cross-sectional data collected from 611 caregivers of girls aged 9-17 in Dhaka. Survey data was collected in November and December 2023. Caregivers were recruited via Facebook and Instagram ads and interviewed through the Facebook Messenger App. About one-third of caregivers reported that their child had been vaccinated. We conducted bivariate and multivariate analyses to assess the relationships between the caregivers' motivation, ability, exposure to the campaign and their child's vaccination status. Adjusted odds ratios from logistic regression analyses, suggest that caregivers' motivation, ability, and exposure to the multimedia campaign contributed to vaccine uptake. Caregivers' motivation to get their child vaccinated was high (74%) but their ability was low (20%). Exposure to campaign messages had a dose-response relationship with vaccine adoption. However, 48% of caregivers remained unexposed to the multimedia campaign. We discuss challenges that the government's HPV vaccination program is likely to face and identify program-related research questions that are important to answer for the success of future vaccination efforts.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2447105"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11730613/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142957495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-02-04DOI: 10.1080/21645515.2025.2454076
Yi Li, Ziwei Liu, Liangru Zhou, Ruifeng Li
The effective implementation of vaccination heavily depends on the society's willingness to pay (WTP). There is currently a dearth of comprehensive evidence about WTP for vaccines in China. This systematic review aims to review studies on the WTP for vaccines, to summarize factors affect WTP in China. Base-case analysis and Sensitivity analysis of WTP for every vaccine were estimated via single-arm Bayesian meta-analysis. A total of 28 studies were included for systematic review. The point estimates and 95% Credible Interval of pooled WTP for influenza and HPV (9-valent) vaccine were $27.409 (23.230, 31.486), $464.707 (441.355, 489.456). Influencing factors to WTP were age, income, peer influence, health condition and etc. Future research should give focus to improving sample representativeness and survey tool, conducting intervention trials, identifying effective methods to promote WTP.
{"title":"Willingness to pay for vaccines in China: A systematic review and single-arm Bayesian meta-analysis.","authors":"Yi Li, Ziwei Liu, Liangru Zhou, Ruifeng Li","doi":"10.1080/21645515.2025.2454076","DOIUrl":"10.1080/21645515.2025.2454076","url":null,"abstract":"<p><p>The effective implementation of vaccination heavily depends on the society's willingness to pay (WTP). There is currently a dearth of comprehensive evidence about WTP for vaccines in China. This systematic review aims to review studies on the WTP for vaccines, to summarize factors affect WTP in China. Base-case analysis and Sensitivity analysis of WTP for every vaccine were estimated via single-arm Bayesian meta-analysis. A total of 28 studies were included for systematic review. The point estimates and 95% Credible Interval of pooled WTP for influenza and HPV (9-valent) vaccine were $27.409 (23.230, 31.486), $464.707 (441.355, 489.456). Influencing factors to WTP were age, income, peer influence, health condition and etc. Future research should give focus to improving sample representativeness and survey tool, conducting intervention trials, identifying effective methods to promote WTP.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2454076"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11796539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143190986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-02-06DOI: 10.1080/21645515.2025.2460844
Josheili Y Llavona-Ortiz, Lauren J Van Scoy, Benjamin Fogel, Casey Pinto, Jamelia Graham, William A Calo
Pandemic-related disruptions in primary care delayed important discussions between providers and parents about routine vaccinations. Conversations have become even more challenging since the COVID-19 pandemic due to increased vaccine hesitancy. This qualitative study explored changes in human papillomavirus (HPV) vaccine conversations within the context of the pandemic from the perspective of primary care team members (PCTMs). Twenty-five PCTMs serving children between 9 and 17 y old in Pennsylvania during the pandemic were conveniently sampled. PCTMs rated their confidence and agreement related to HPV vaccine conversations and pandemic impact. Semi-structured interview questions assessed changes in their HPV vaccine conversations throughout the pandemic. Open-ended questions inquired about PCTMs' thoughts on the COVID-19 pandemic and if or how it impacted HPV vaccination uptake in their practice. Data were collected from May to July 2024. Verbatim transcriptions were analyzed using both inductive and deductive approaches to thematic analysis. Participants were 44% pediatricians, 50% had ≥20 y experience, and 68% were White. Six themes emerged: (1) parents show a range of reactions about HPV vaccination; (2) disruptions in healthcare visits and heightened parental concerns impede vaccination; (3) PCTMs notice clear changes in vaccine acceptance rates; (4) reasons for vaccination refusal have not substantially changed as a result of the pandemic; (5) importance of interpersonal relationships with parents; and (6) PCTM burnout impacts conversations. The pandemic added challenges to HPV vaccine conversations with parents. Findings from this study can be used to refine existing communication approaches to improve HPV vaccine conversations in primary care.
{"title":"\"The big topic is COVID\": A qualitative study about changes in HPV vaccine conversations between parents and primary care team members throughout the COVID-19 pandemic.","authors":"Josheili Y Llavona-Ortiz, Lauren J Van Scoy, Benjamin Fogel, Casey Pinto, Jamelia Graham, William A Calo","doi":"10.1080/21645515.2025.2460844","DOIUrl":"https://doi.org/10.1080/21645515.2025.2460844","url":null,"abstract":"<p><p>Pandemic-related disruptions in primary care delayed important discussions between providers and parents about routine vaccinations. Conversations have become even more challenging since the COVID-19 pandemic due to increased vaccine hesitancy. This qualitative study explored changes in human papillomavirus (HPV) vaccine conversations within the context of the pandemic from the perspective of primary care team members (PCTMs). Twenty-five PCTMs serving children between 9 and 17 y old in Pennsylvania during the pandemic were conveniently sampled. PCTMs rated their confidence and agreement related to HPV vaccine conversations and pandemic impact. Semi-structured interview questions assessed changes in their HPV vaccine conversations throughout the pandemic. Open-ended questions inquired about PCTMs' thoughts on the COVID-19 pandemic and if or how it impacted HPV vaccination uptake in their practice. Data were collected from May to July 2024. Verbatim transcriptions were analyzed using both inductive and deductive approaches to thematic analysis. Participants were 44% pediatricians, 50% had ≥20 y experience, and 68% were White. Six themes emerged: (1) parents show a range of reactions about HPV vaccination; (2) disruptions in healthcare visits and heightened parental concerns impede vaccination; (3) PCTMs notice clear changes in vaccine acceptance rates; (4) reasons for vaccination refusal have not substantially changed as a result of the pandemic; (5) importance of interpersonal relationships with parents; and (6) PCTM burnout impacts conversations. The pandemic added challenges to HPV vaccine conversations with parents. Findings from this study can be used to refine existing communication approaches to improve HPV vaccine conversations in primary care.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2460844"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143366299","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vaccination is the most effective measure to prevent Chlamydia infection. However, to date, no vaccine has successfully completed the rigorous clinical trial process and gained regulatory approval for use in clinical practice. Scholars have been working on a safe and effective Chlamydia vaccine. In order to better grasp, the global frontiers and development trends in this field, a comprehensive bibliometric analysis was carried out. A total of 234 publications closely regarding Chlamydia vaccines were culled from the Web of Science Core Collection database, and the bibliometric information was then extracted with CiteSpace and VOSviewer software. After measurement analysis, the most influential papers were identified in this area, including highly cited papers, references with strong citation burst, and high co-citated papers. Vaccine has published the most literature on Chlamydia vaccines. Only scholars from 39 countries/regions have been engaged in studying Chlamydia vaccines. The USA is the most prolific country and has the highest collaborative strength. The current research area has focused on protective immunity and immunopathological response. Major outer membrane protein (MOMP) is the most common target vaccine antigen. This study reveals the status of literature and highlights emerging trends in this field, which helps researchers seek insights into this area and serve as a reference guide for further investigations.
{"title":"Profile of <i>Chlamydia</i> vaccine research: A bibliometric analysis.","authors":"Xuemei Wang, Qian Wang, Yidan Gao, Lijuan Jiang, Lingli Tang","doi":"10.1080/21645515.2025.2459459","DOIUrl":"10.1080/21645515.2025.2459459","url":null,"abstract":"<p><p>Vaccination is the most effective measure to prevent <i>Chlamydia</i> infection. However, to date, no vaccine has successfully completed the rigorous clinical trial process and gained regulatory approval for use in clinical practice. Scholars have been working on a safe and effective <i>Chlamydia</i> vaccine. In order to better grasp, the global frontiers and development trends in this field, a comprehensive bibliometric analysis was carried out. A total of 234 publications closely regarding <i>Chlamydia</i> vaccines were culled from the Web of Science Core Collection database, and the bibliometric information was then extracted with CiteSpace and VOSviewer software. After measurement analysis, the most influential papers were identified in this area, including highly cited papers, references with strong citation burst, and high co-citated papers. <i>Vaccine</i> has published the most literature on <i>Chlamydia</i> vaccines. Only scholars from 39 countries/regions have been engaged in studying <i>Chlamydia</i> vaccines. The USA is the most prolific country and has the highest collaborative strength. The current research area has focused on protective immunity and immunopathological response. Major outer membrane protein (MOMP) is the most common target vaccine antigen. This study reveals the status of literature and highlights emerging trends in this field, which helps researchers seek insights into this area and serve as a reference guide for further investigations.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2459459"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11801346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143191066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-01-14DOI: 10.1080/21645515.2025.2450858
Dania Comparcini, Giancarlo Cicolini, Melania Totaro, Letizia Governatori, Francesco Pastore, Daniela Miniscalco, Maria Elena Flacco, Eustachio Cuscianna, Silvio Tafuri, Valentina Simonetti
Achieving safe influenza vaccination coverage among pregnant and breastfeeding women is a global health goal due to the potential risks of serious influenza for both mother and child. However, vaccine hesitancy remains a significant barrier to vaccination uptake. Since anxiety represents a determinant in vaccine decision-making, this study aimed to assess influenza vaccination hesitancy and anxiety levels in this population and to explore the association between women's characteristics, their reluctance, and anxiety levels. A multicentre, cross-sectional study was conducted between February and June 2022 using structured phone interviews to assess: (1) socio-demographics and clinical history; (2) anti-flu vaccination status, previous anti-flu vaccination, and Sars-CoV-2 infection history; (3) insights into influenza vaccination during pregnancy; (4) attitudes toward anti-flu vaccination, using the Vaccination Attitudes Examination (VAX) Scale; (5) anxiety levels, measured by the Self-Rating Anxiety Scale (SAS). Among the 387 participants, 22.8% were already vaccinated or expressed willingness to be vaccinated against influenza, and 54% had an anxiety disorder. While anxiety was not significantly associated with vaccine hesitancy, ongoing pregnancy emerged as an independent predictor of anxiety. Higher educational levels, ongoing pregnancy, already being vaccinated or willingness to get vaccinated, and being employed were associated with reduced vaccine hesitancy, while prior SARS-CoV-2 infection with increased hesitancy. Fear of unpredictable events and lack of healthcare professionals' recommendations emerged as reasons for vaccine reluctance. Given the low coverage rates, these findings highlight the need for health services to enhance vaccination efforts and provide clear recommendations to counter misinformation and ensure accurate vaccine safety information.
{"title":"Influenza vaccination hesitancy and related factors among pregnant and breastfeeding women: A cross-sectional study.","authors":"Dania Comparcini, Giancarlo Cicolini, Melania Totaro, Letizia Governatori, Francesco Pastore, Daniela Miniscalco, Maria Elena Flacco, Eustachio Cuscianna, Silvio Tafuri, Valentina Simonetti","doi":"10.1080/21645515.2025.2450858","DOIUrl":"10.1080/21645515.2025.2450858","url":null,"abstract":"<p><p>Achieving safe influenza vaccination coverage among pregnant and breastfeeding women is a global health goal due to the potential risks of serious influenza for both mother and child. However, vaccine hesitancy remains a significant barrier to vaccination uptake. Since anxiety represents a determinant in vaccine decision-making, this study aimed to assess influenza vaccination hesitancy and anxiety levels in this population and to explore the association between women's characteristics, their reluctance, and anxiety levels. A multicentre, cross-sectional study was conducted between February and June 2022 using structured phone interviews to assess: (1) socio-demographics and clinical history; (2) anti-flu vaccination status, previous anti-flu vaccination, and Sars-CoV-2 infection history; (3) insights into influenza vaccination during pregnancy; (4) attitudes toward anti-flu vaccination, using the Vaccination Attitudes Examination (VAX) Scale; (5) anxiety levels, measured by the Self-Rating Anxiety Scale (SAS). Among the 387 participants, 22.8% were already vaccinated or expressed willingness to be vaccinated against influenza, and 54% had an anxiety disorder. While anxiety was not significantly associated with vaccine hesitancy, ongoing pregnancy emerged as an independent predictor of anxiety. Higher educational levels, ongoing pregnancy, already being vaccinated or willingness to get vaccinated, and being employed were associated with reduced vaccine hesitancy, while prior SARS-CoV-2 infection with increased hesitancy. Fear of unpredictable events and lack of healthcare professionals' recommendations emerged as reasons for vaccine reluctance. Given the low coverage rates, these findings highlight the need for health services to enhance vaccination efforts and provide clear recommendations to counter misinformation and ensure accurate vaccine safety information.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2450858"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11740437/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142985146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2024-12-22DOI: 10.1080/21645515.2024.2440956
Rui Zhang, Ngai Sze Wong, Sze Long Chung, Chi Keung Kwan, Tsz Ho Kwan, Shui Shan Lee
Human papillomavirus (HPV) vaccination could reduce HPV infection in men who have sex with men (MSM), but the published statistics on HPV vaccination uptake in MSM were scarce globally. This study estimated the uptake and profiled the service preferences of HPV vaccination of Chinese MSM in Hong Kong. Adult MSM were recruited through non-governmental organizations (NGOs) and online channels for completing an online baseline survey. Factors associated with self-reported history of HPV vaccination were identified using multivariable stepwise logistic regression model. Totally 701 Chinese MSM completed the online baseline survey, with the median age of 30 y (interquartile range [IQR] 26-35, range 18-67), and 23% of them had received HPV vaccination. More than half of vaccinated MSM (72%) rated convenient or very convenient for local HPV vaccination services. Among unvaccinated MSM, 50% considered high cost of HPV vaccine as the barrier of vaccination, 67% expressed willingness to pay below USD 128 per vaccine dose, and 65% preferred receiving vaccination in private clinics. MSM who had taken HIV pre-exposure prophylaxis (PrEP) (p < .001), had been tested for HPV (p = .018), and had (p = .005) multiple regular sex partners in the past 6 months were more likely to be vaccinated. The HPV vaccination uptake of Chinese MSM in Hong Kong remains low (23%), and high HPV vaccine cost is the main barrier. Preventive behaviors (HIV PrEP use and HPV testing) and high-risk sexual behavior (multiple regular sex partners) are potential targets for intervention to increase the uptake of HPV vaccination in MSM.
{"title":"Uptake and service preferences of human papillomavirus vaccination in men who have sex with men.","authors":"Rui Zhang, Ngai Sze Wong, Sze Long Chung, Chi Keung Kwan, Tsz Ho Kwan, Shui Shan Lee","doi":"10.1080/21645515.2024.2440956","DOIUrl":"https://doi.org/10.1080/21645515.2024.2440956","url":null,"abstract":"<p><p>Human papillomavirus (HPV) vaccination could reduce HPV infection in men who have sex with men (MSM), but the published statistics on HPV vaccination uptake in MSM were scarce globally. This study estimated the uptake and profiled the service preferences of HPV vaccination of Chinese MSM in Hong Kong. Adult MSM were recruited through non-governmental organizations (NGOs) and online channels for completing an online baseline survey. Factors associated with self-reported history of HPV vaccination were identified using multivariable stepwise logistic regression model. Totally 701 Chinese MSM completed the online baseline survey, with the median age of 30 y (interquartile range [IQR] 26-35, range 18-67), and 23% of them had received HPV vaccination. More than half of vaccinated MSM (72%) rated convenient or very convenient for local HPV vaccination services. Among unvaccinated MSM, 50% considered high cost of HPV vaccine as the barrier of vaccination, 67% expressed willingness to pay below USD 128 per vaccine dose, and 65% preferred receiving vaccination in private clinics. MSM who had taken HIV pre-exposure prophylaxis (PrEP) (<i>p</i> < .001), had been tested for HPV (<i>p</i> = .018), and had (<i>p</i> = .005) multiple regular sex partners in the past 6 months were more likely to be vaccinated. The HPV vaccination uptake of Chinese MSM in Hong Kong remains low (23%), and high HPV vaccine cost is the main barrier. Preventive behaviors (HIV PrEP use and HPV testing) and high-risk sexual behavior (multiple regular sex partners) are potential targets for intervention to increase the uptake of HPV vaccination in MSM.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2440956"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2024-12-20DOI: 10.1080/21645515.2024.2435156
Hao Lei, Beidi Niu, Zhou Sun, Yaojing Wang, Xinren Che, Shengqiang Du, Yan Liu, Ke Zhang, Shi Zhao, Shigui Yang, Zhe Wang, Gang Zhao
From 2020, influenza viruses circulation was largely affected by the global coronavirus disease (COVID-19) pandemic, notably leading to the extinction of the B/Yamagata lineage and raising questions about the relevance of the quadrivalent influenza vaccine, which includes this lineage. Evaluating vaccine effectiveness (VE) against influenza infections is important to inform future vaccine programs. A test-negative case-control study was conducted in five tertiary hospitals in Hangzhou, the capital city of Zhejiang province, China, enrolling medically-attended patients aged >6 months who presented with influenza-like illness (ILI) from October 1, 2023, to March 31, 2024. The VE was estimated using multivariate logistic regression models adjusted for sex, age, influenza detection methods, and influenza testing timing. Of the 157,291 medically-attended ILI participants enrolled 56,704 (36%) tested positive for influenza. Adjusted overall VE against any medically-attended influenza infection was 48% (95% Confidence interval [CI]: 46%-51%). The overall VE of the trivalent inactivated influenza vaccine (IIV3) was 59% (95% CI: 50%-66%), followed by the trivalent live attenuated vaccine (LAIV3) (VE = 53%, 95% CI: 42%-62%) and quadrivalent inactivated influenza vaccine (IIV4) (VE = 47%, 95% CI: 45%-50%). IIV3 provided even better protection against medically-attended influenza B infection than IIV4 (VE = 87%, 95% CI: 81%-92% for IIV3 versus VE = 53%, 95% CI: 50%-57% for IIV4). In the 2023/24 season in Hangzhou, China, the influenza vaccine offered moderate protection during a major epidemic. The results supported the World Health Organization recommendation to exclude the B/Yamagata lineage antigen in quadrivalent influenza vaccines in 2023.
{"title":"Influenza vaccine effectiveness against medically-attended influenza infection in 2023/24 season in Hangzhou, China.","authors":"Hao Lei, Beidi Niu, Zhou Sun, Yaojing Wang, Xinren Che, Shengqiang Du, Yan Liu, Ke Zhang, Shi Zhao, Shigui Yang, Zhe Wang, Gang Zhao","doi":"10.1080/21645515.2024.2435156","DOIUrl":"https://doi.org/10.1080/21645515.2024.2435156","url":null,"abstract":"<p><p>From 2020, influenza viruses circulation was largely affected by the global coronavirus disease (COVID-19) pandemic, notably leading to the extinction of the B/Yamagata lineage and raising questions about the relevance of the quadrivalent influenza vaccine, which includes this lineage. Evaluating vaccine effectiveness (VE) against influenza infections is important to inform future vaccine programs. A test-negative case-control study was conducted in five tertiary hospitals in Hangzhou, the capital city of Zhejiang province, China, enrolling medically-attended patients aged >6 months who presented with influenza-like illness (ILI) from October 1, 2023, to March 31, 2024. The VE was estimated using multivariate logistic regression models adjusted for sex, age, influenza detection methods, and influenza testing timing. Of the 157,291 medically-attended ILI participants enrolled 56,704 (36%) tested positive for influenza. Adjusted overall VE against any medically-attended influenza infection was 48% (95% Confidence interval [CI]: 46%-51%). The overall VE of the trivalent inactivated influenza vaccine (IIV3) was 59% (95% CI: 50%-66%), followed by the trivalent live attenuated vaccine (LAIV3) (VE = 53%, 95% CI: 42%-62%) and quadrivalent inactivated influenza vaccine (IIV4) (VE = 47%, 95% CI: 45%-50%). IIV3 provided even better protection against medically-attended influenza B infection than IIV4 (VE = 87%, 95% CI: 81%-92% for IIV3 versus VE = 53%, 95% CI: 50%-57% for IIV4). In the 2023/24 season in Hangzhou, China, the influenza vaccine offered moderate protection during a major epidemic. The results supported the World Health Organization recommendation to exclude the B/Yamagata lineage antigen in quadrivalent influenza vaccines in 2023.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2435156"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142865663","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-01-06DOI: 10.1080/21645515.2024.2444697
Fang-Ju Huang, Ye-Ying Fang, Jia-Ying Wen, Jian-Jun Li, Qian Lin, Qin-Yan Su, Yi-Yang Chen, Lei Wang, Jian-Jia Zeng, Bang-Teng Chi, Rong-Quan He, Di-Yuan Qin, Li-Hua Yang, Gang Chen
Cholangiocarcinoma (CCA) is a highly malignant hepatobiliary tumor characterized by limited treatment options and poor prognosis. The recent rise of immunotherapy has significantly influenced research in this field. This study presents a bibliometric analysis of 416 articles retrieved from the WOSCC, Wan fang Data, CNKI and VIP databases, spanning contributions from 32 countries, 589 institutions and 3,200 authors. The analysis identified "PD-L1," "PD-1" and "pembrolizumab" as central research foci, while "immune checkpoint inhibitors," "tumor immune microenvironment," "tertiary lymphoid structures" and "durvalumab" emerged as key areas of interest. These findings emphasize the pivotal role of immunotherapy in improving survival outcomes for CCA, and they highlight the significance of tertiary lymphoid structures within the tumor microenvironment as a promising target for future research. This study offers a strategic overview of the evolving landscape of CCA immunotherapy, providing valuable insights to guide future scientific endeavors in this domain.
{"title":"From PD-1/PD-L1 to tertiary lymphoid structures: Paving the way for precision immunotherapy in cholangiocarcinoma treatment.","authors":"Fang-Ju Huang, Ye-Ying Fang, Jia-Ying Wen, Jian-Jun Li, Qian Lin, Qin-Yan Su, Yi-Yang Chen, Lei Wang, Jian-Jia Zeng, Bang-Teng Chi, Rong-Quan He, Di-Yuan Qin, Li-Hua Yang, Gang Chen","doi":"10.1080/21645515.2024.2444697","DOIUrl":"https://doi.org/10.1080/21645515.2024.2444697","url":null,"abstract":"<p><p>Cholangiocarcinoma (CCA) is a highly malignant hepatobiliary tumor characterized by limited treatment options and poor prognosis. The recent rise of immunotherapy has significantly influenced research in this field. This study presents a bibliometric analysis of 416 articles retrieved from the WOSCC, Wan fang Data, CNKI and VIP databases, spanning contributions from 32 countries, 589 institutions and 3,200 authors. The analysis identified \"PD-L1,\" \"PD-1\" and \"pembrolizumab\" as central research foci, while \"immune checkpoint inhibitors,\" \"tumor immune microenvironment,\" \"tertiary lymphoid structures\" and \"durvalumab\" emerged as key areas of interest. These findings emphasize the pivotal role of immunotherapy in improving survival outcomes for CCA, and they highlight the significance of tertiary lymphoid structures within the tumor microenvironment as a promising target for future research. This study offers a strategic overview of the evolving landscape of CCA immunotherapy, providing valuable insights to guide future scientific endeavors in this domain.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2444697"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142933382","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-12-01Epub Date: 2025-01-22DOI: 10.1080/21645515.2025.2454078
Ting Zhang, Zhongquan Jian, Juan Chen, Dongzi Xu, Xiaoyi Yang, Yan Lu, Shu Yan, Lizi Pan, Qingqiang Wu, Zhaolian Ouyang
mRNA vaccines offer groundbreaking technological advantages and broad application potential. Their rapid advancement, particularly during the COVID-19 pandemic, is the result of decades of research and numerous technological breakthroughs. These discoveries build upon each other, forming dense, interconnected networks of progress. Studying the technological development paths of mRNA vaccines is therefore essential. Main path analysis (MPA) is particularly effective for mapping out development trajectories within complex and interconnected networks, which serves as a powerful tool for identifying key nodes and innovations. This study introduces a novel approach to extracting main paths from a patent citation network in the mRNA vaccine field. Initially, we shielded edges connecting the origin and terminus patents. Subsequently, we extracted the main paths from intermediate patents, and then, we reintegrated the edges connecting the origin and terminus patents based on the citation relationships, resulting in a comprehensive extraction of the main paths. The research findings indicate a consistency among the global main paths, global key-route main paths, local forward main paths, and local key-route main paths within the mRNA vaccine field. The patents on the main paths predominantly focus on nucleic acid modifications and delivery systems. The local backward main paths identify a greater number of patents, especially those related to litigation, offering a richer and more diverse set of technological insights. This study significantly advances the methodology of MPA, with the innovative shielding technique offering a fresh perspective for navigating complex networks and providing a deeper understanding of technological development in the mRNA vaccine domain.
{"title":"Efficiency enhancement in main path extraction in mRNA vaccine field: A novel approach leveraging intermediate patents, with shielding origin and terminus patent edges.","authors":"Ting Zhang, Zhongquan Jian, Juan Chen, Dongzi Xu, Xiaoyi Yang, Yan Lu, Shu Yan, Lizi Pan, Qingqiang Wu, Zhaolian Ouyang","doi":"10.1080/21645515.2025.2454078","DOIUrl":"https://doi.org/10.1080/21645515.2025.2454078","url":null,"abstract":"<p><p>mRNA vaccines offer groundbreaking technological advantages and broad application potential. Their rapid advancement, particularly during the COVID-19 pandemic, is the result of decades of research and numerous technological breakthroughs. These discoveries build upon each other, forming dense, interconnected networks of progress. Studying the technological development paths of mRNA vaccines is therefore essential. Main path analysis (MPA) is particularly effective for mapping out development trajectories within complex and interconnected networks, which serves as a powerful tool for identifying key nodes and innovations. This study introduces a novel approach to extracting main paths from a patent citation network in the mRNA vaccine field. Initially, we shielded edges connecting the origin and terminus patents. Subsequently, we extracted the main paths from intermediate patents, and then, we reintegrated the edges connecting the origin and terminus patents based on the citation relationships, resulting in a comprehensive extraction of the main paths. The research findings indicate a consistency among the global main paths, global key-route main paths, local forward main paths, and local key-route main paths within the mRNA vaccine field. The patents on the main paths predominantly focus on nucleic acid modifications and delivery systems. The local backward main paths identify a greater number of patents, especially those related to litigation, offering a richer and more diverse set of technological insights. This study significantly advances the methodology of MPA, with the innovative shielding technique offering a fresh perspective for navigating complex networks and providing a deeper understanding of technological development in the mRNA vaccine domain.</p>","PeriodicalId":49067,"journal":{"name":"Human Vaccines & Immunotherapeutics","volume":"21 1","pages":"2454078"},"PeriodicalIF":4.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}